Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1641 1645 1733
This examiner grants 64% of resolved cases
Oluwatosin A Ogunbiyi performs examinations in Tech Center 1700 and Art Unit 1641. There are 934 resolved cases for this examiner in the database. This total of 934 cases provides a foundation for analyzing the examiner's history. Practitioners may use these results to anticipate the progression of future applications through the patent office in this technical area.
The data indicates an allowance rate of 63.7 percent. This 63.7 percent figure represents the frequency with which applications result in a patent grant. The interview lift is recorded at 41.4 percent. This 41.4 percent lift shows the increase in the probability of allowance following a formal interview. This metric suggests that verbal communication with the examiner is a tool for resolving outstanding prosecution hurdles.
The median days to allowance is 1061. This 1061 day duration measures the time required for the median application to reach a final grant. Applicants should account for this timeline when planning their intellectual property strategy. The metrics for Art Unit 1641 suggest a specific environment for applications assigned to this examiner, characterized by the recorded allowance and pendency figures.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18705007 | A Subunit Cryptococcus Vaccine | Non-Final OA | University of Massachusetts |
| 18826093 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18418897 | LIPOTEICHOIC ACID FROM STAPHYLOCOCCUS EPIDERMIDIS AND ITS USE TO MODULATE NEURONAL ACTIVITY VIA PD-1 INHIBITORY SIGNALLING IN NEURONS | Non-Final OA | Northwestern University |
| 17434349 | TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM | Final Rejection | The General Hospital Corporation |
| 18741976 | LYME DISEASE RNA VACCINE | Non-Final OA | SANOFI PASTEUR INC. |
| 18697325 | ENGINEERED VECTORS AND ORGANISMS CONTAINING THE SAME FOR ISOFLAVONE CONVERSION IN THE GUT | Non-Final OA | Board of Regents, The University of Texas System |
| 18863566 | IMMUNOBIOTICS FOR PREVENTING BACTERIAL PNEUMONIA AND METHODS OF USING THE SAME | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18293016 | MICROORGANISMS DISPLAYING VIRAL DECOY RECEPTORS | Non-Final OA | EVONIK OPERATIONS GMBH |
| 18739401 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | Non-Final OA | Pfizer Inc. |
| 18711074 | TREATMENT OF PAIN | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18852553 | Engineered Probiotic Delivery System for Anti-SARS-COV-2 Treatment and Immunity Against Viruses | Non-Final OA | University of Cincinnati |
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | Final Rejection | Research Development Foundation |
| 17767476 | IMMUNOGENIC PEPTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF MALARIA | Non-Final OA | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy